Anti-viral therapy in Alzheimer's disease will investigate the efficacy of treating patients
with mild Alzheimer's disease with the U.S.A marketed generic anti-viral drug Valtrex
(valacyclovir, 500mg oral tablet). Valacyclovir, titrated to 4 grams per day, repurposed to
treat Alzheimer's disease, will be compared to matching placebo in the treatment of 130 mild
AD patients (65 valacyclovir, 65 placebo) who test positive for herpes simplex virus-1 (HSV1)
or herpes simplex virus-2 (HSV2). The study will be a randomized, double-blind, 18-month
Phase II proof of concept trial.
Phase:
Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborators:
National Institute on Aging (NIA) National Institutes of Health (NIH)